Drug	Schedule
Amphetamine (1100)	П
Methamphetamine (1105)	II
Methylphenidate (1724)	П
Amobarbital (2125)	II
Pentobarbital (2270)	II
Secobarbital (2315)	П
1-Phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	П
Phenylacetone (8501)	II
1-	II
Piperidinocyclohexanecarbonitr-	
ile (8603).	
Cocaine (9041)	II
Codeine (9050)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Benzoylecgonine (9180)	II
Ethylmorphine (9190)	II II
Hydrocodone (9193)	ii
Isomethadone (9226)	ii
Meperidine (9230)	ii
Meperidine intermediate-A (9232)	ii
Meperidine intermediate-B (9233)	ii
Methadone (9250)	l ii
Methadone intermediate (9254)	
Dextropropoxyphene, bulk, (non-dosage forms) (9273).	II
Morphine (9300)	п
Thebaine (9333)	l ii
Levo-alphacetylmethadol (9648)	l ii
Oxymorphone (9652)	l ii

The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug testing and analysis.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 27, 2010.

Dated: October 19, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–27018 Filed 10–25–10; 8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 8, 2009 Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Tetrahydrocannabinols (7370) Dihydromorphine (9145) Dihydrocodeine (9120) Oxycodone (9143) Hydromorphone (9150) Hydrocodone (9193) Remifentanil (9739) Sufentanil (9740)	

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

In reference to drug code 7370 the company plans to bulk manufacture a synthetic Tetrahydrocannabinol. No other activity for this drug is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 27, 2010.

Dated: October 19, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator,Office of Diversion Control,Drug Enforcement Administration

[FR Doc. 2010–27021 Filed 10–25–10; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 3, 2010, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Gamma Hydroxybutyric Acid I (2010). Tetrahydrocannabinols (7370) I	
Tetrahydrocannabinols (7370) I	
Dihydromorphine (9145) I	
Difenoxin (9168) I Propiram (9649) I	
Amphetamine (1100) II	
Methamphetamine (1105) II Lisdexamfetamine (1205) II	
Methylphenidate (1724) II	
Nabilone (7379) II Cocaine (9041) II	
Codeine (9050) II	
Dihydrocodeine (9120) II Oxycodone (9143) II	
Hydromorphone (9150) II	
Ecgonine (9180) II Hydrocodone (9193) II	
Meperidine (9230) II	
Methadone (9250) II	
Methadone intermediate (9254) II Morphine (9300) II	
Thebaine (9333) II	
Oxymorphone (9652) II Noroxymorphone (9668) II	
Alfentanil (9737) II	
Remifentanil (9739) II	
Sufentanil (9740) II Fentanyl (9801) II	

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such a controlled substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 27, 2010.

Dated: October 19, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–27019 Filed 10–25–10; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 16, 2010, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application